相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas
Ulrik Lassen et al.
ACTA ONCOLOGICA (2011)
KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients
Rui Feng Xu et al.
BIOMEDICINE & PHARMACOTHERAPY (2011)
Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma
Lars Henrik Jensen et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
Cholangiocarcinoma: Update and future perspectives
Manuela Gatto et al.
DIGESTIVE AND LIVER DISEASE (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study
Birgit Gruenberger et al.
LANCET ONCOLOGY (2010)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Preliminary Experience of Cetuximab in the Treatment of Advanced-Stage Biliary Tract Cancer
Ping-Ying Chang et al.
ONKOLOGIE (2010)
US Food and Drug Administration approval: Panitumumab for epidermal growth factor receptor-expressing metestetic colorectal carcinoma with progression following fluropyrimidine-, oxelipletin-, and irinotecen-containing chemotherapy regimens
Ruthann M. Giusti et al.
CLINICAL CANCER RESEARCH (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials
F. Eckel et al.
BRITISH JOURNAL OF CANCER (2007)
Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver
Tsai-Wang Huang et al.
ONKOLOGIE (2007)
Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas
Bernard Paule et al.
ONCOLOGY (2007)
Gemcitabine in combination with EGF-receptor antibody (cetuximab) as a treatment of cholangiocarcinoma: a case report
Martin F. Sprinzl et al.
BMC CANCER (2006)
Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma
MP Bralet et al.
CLINICAL ONCOLOGY (2006)
Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers
K Nakazawa et al.
JOURNAL OF PATHOLOGY (2005)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
LB Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
A Tannapfel et al.
GUT (2003)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
